MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-13-2026
BioNano Genomics Cost of Revenue 2011-2026 | BNGO
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue BioNano Genomics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.3 M | 30.4 M | 26.6 M | 21.9 M | 14.1 M | 5.73 M | 6.77 M | 8.71 M | 6.03 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 30.4 M | 5.73 M | 15.1 M |
Quarterly Cost of Revenue BioNano Genomics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.44 M | 4 M | 3.26 M | 3.52 M | - | 14.5 M | 5.19 M | 5.94 M | - | 6.57 M | 6.35 M | 5.34 M | - | 5.41 M | 5.2 M | 4.84 M | - | 3.5 M | 2.42 M | 2.12 M | - | 1.46 M | 603 K | 856 K | 1.69 M | 2.38 M | 1.56 M | 1.15 M | 2.99 M | 3.07 M | 1.81 M | 841 K | 1.5 M | 1.69 M | 1.64 M | 1.21 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.5 M | 603 K | 3.42 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.37 B | $ 203.29 | -0.59 % | $ 22.6 B | USA |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
222 K | $ 4.99 | 10.89 % | $ 6.64 M | USA |
 |
Castle Biosciences
CSTL
|
71 M | $ 21.13 | 0.24 % | $ 612 M | USA |
 |
Fulgent Genetics
FLGT
|
192 M | $ 18.9 | 2.16 % | $ 582 M | USA |
 |
Aspira Women's Health
AWH
|
3.3 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
8.99 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
ICON Public Limited Company
ICLR
|
6.08 B | $ 145.57 | -4.12 % | $ 11.4 B |  Irlanda |
 |
Guardant Health
GH
|
349 M | $ 130.25 | 0.1 % | $ 16.3 B | USA |
 |
Illumina
ILMN
|
1.47 B | $ 162.88 | 1.78 % | $ 25.2 B | USA |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 23.33 | 2.55 % | $ 1.24 B | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Interpace Biosciences
IDXG
|
14.6 M | $ 1.76 | 1.32 % | $ 7.79 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
361 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
369 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
Lantheus Holdings
LNTH
|
600 M | $ 100.82 | 0.84 % | $ 6.8 B | USA |
 |
Pacific Biosciences of California
PACB
|
114 M | $ 1.4 | 2.19 % | $ 420 M | USA |
 |
Exact Sciences Corporation
EXAS
|
984 M | - | - | $ 19.8 B | USA |
 |
NeoGenomics
NEO
|
413 M | $ 11.29 | -1.35 % | $ 1.45 B | USA |
 |
Myriad Genetics
MYGN
|
248 M | $ 4.47 | -1.43 % | $ 414 M | USA |
 |
Natera
NTRA
|
158 M | $ 218.17 | -2.09 % | $ 29.8 B | USA |
 |
Personalis
PSNL
|
53.9 M | $ 9.8 | 0.51 % | $ 875 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
9.78 B | $ 25.71 | -2.98 % | $ 24.4 B |  Niderland |
 |
Senseonics Holdings
SENS
|
19.5 M | $ 7.32 | -1.48 % | $ 305 M | USA |
 |
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
2.7 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
4.81 M | $ 2.03 | -1.02 % | $ 4.66 M | USA |
 |
Twist Bioscience Corporation
TWST
|
186 M | $ 68.35 | -2.44 % | $ 4.09 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 267.67 | -1.3 % | $ 22.3 B | USA |
 |
Trinity Biotech plc
TRIB
|
40.1 M | $ 0.68 | 2.94 % | $ 244 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K |  Israel |
 |
Neogen Corporation
NEOG
|
473 M | $ 9.22 | -0.81 % | $ 2 B | USA |
 |
Invitae Corporation
NVTA
|
92.8 M | - | - | $ 21.2 M | USA |